Global Acoustic Neuroma Market – Industry Trends and Forecast to 2029

Acoustic Neuroma Market Analysis and Size

The global acoustic neuroma market is expected to witness significant growth during the forecast period. The growth of acoustic neuroma market enhanced by the growing cases of acoustic neuroma and availability of treatment options. In addition, government initiatives and high demand for non-invasive treatment are some of the impacting factors for the growth of acoustic neuroma market. Major market players are launched many new drugs likely to offer market growth opportunities. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global acoustic neuroma market in the forecast period 2022-2029. The expected CAGR of global acoustic neuroma market is tend to be around 7.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Acoustic neuroma, also termed vestibular schwannoma, is a slow-growing begin tumor that develops on the nerve that connects the inner ear to the brain. The tumor results from the hyperactivation of Schwann cells, which ultimately affects the hearing and balance nerves. Symptoms are often subtle and takes time to develop. The common signs and symptoms of the condition are dizziness, hearing loss and ringing in the ears. It is of great importance to the healthcare sector.

Acoustic Neuroma Market Scope and Segmentation

Global Acoustic Neuroma Market Dynamics

Drivers

• Increased Research and Clinical Activities

Increased R&D in the field of acoustic neuroma drives the market growth. According to the article published in Science Daily, in patients diagnosed with the most common form of primary brain tumors such as meningioma and acoustic neuroma brain tumors, drugs that are developed to treat AIDS and HIV can be used.  

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Rising Incidence of Neuroma

Approximately 1-20 people are diagnosed each year with an acoustic neuroma. They are more common in middle-aged adults but are rare in children. In addition, neuromas are more common in women than men. It affect adults between the age group of 30 to 60 and usually have no obvious cause, although few number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).

• Increasing Demand for Retail Pharmacies

The rise in the number of acoustic neuroma therapeutics delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global acoustic neuroma market over a forecast period.

• High Cost

The huge expenditure associated with acoustic neuroma treatment medications surely hamper the market growth.

This global acoustic neuroma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global acoustic neuroma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Acoustic Neuroma Market         

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

In the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge future growth due to the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the acoustic neuroma market.

Global Acoustic Neuroma Market Scope

The global acoustic neuroma market is segmented on the basis of treatment type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Medicines
• Radiation Therapy
• Surgery

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Acoustic Neuroma Market Regional Analysis/Insights

The global acoustic neuroma market is analysed and market size insights and trends are provided by treatment type, distribution channel and end-user as referenced above.

The major countries covered in the global acoustic neuroma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for acoustic neuroma market throughout the forecasted period due to the high adoption of technologies and rise in patient assistance programs.

Asia-Pacific dominates the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Acoustic Neuroma Market Share Analysis

The global acoustic neuroma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global acoustic neuroma market

Key players operating in the global acoustic neuroma market include:

• PLx Pharma Inc (U.S.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Amgen Inc (U.S.)
• Advanced Bionics AG (Switzerland)
• Accuray Incorporated (U.S.)
• Teva Pharmaceuticals Industries Ltd (Israel)
• Mylan N.V. (U.S.)
• General Electric (U.S.)
• Siemens Healthcare GmbH (U.S.)
• Koninklijke Philips N.V (U.S.)
• Shimadzu Corporation (Japan)
• Toshiba Medical Systems Corporation (Japan)

SKU-53546